A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Status:
Completed
Trial end date:
2021-10-07
Target enrollment:
Participant gender:
Summary
This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability,
pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid
tumors or B-cell lymphoma. This study will provide a basis for further clinical development
of CN1.